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Abstract 26 
Background: The purpose of this study is to unveil whether azole antifungals used in 27 
agriculture, similar to the clinical azoles used in humans, can evoke resistance among 28 
relevant human pathogens like Aspergillus fumigatus, an ubiquitous agent in nature. 29 
Additionally, cross-resistance with clinical azoles was investigated. Antifungal 30 
susceptibility testing of environmental and clinical isolates of A. fumigatus was 31 
performed according to the CLSI M38-A2 protocol. In vitro induction assays were 32 
conducted involving daily incubation of susceptible A. fumigatus isolates, at 35ºC and 33 
180 rpm, in fresh GYEP broth medium supplemented with Prochloraz (PCZ), a potent 34 
agricultural antifungal, for a period of 30 days. Minimal inhibitory concentrations 35 
(MIC) of PCZ and clinical azoles were monitored every ten days. In order to assess the 36 
stability of the developed MIC, the strains were afterwards sub-cultured for an 37 
additional 30 days in the absence of antifungal. Along the in vitro induction process, 38 
microscopic and macroscopic cultural observations were registered.  39 
Results: MIC of PCZ increased over 32 times in just ten days after initial PCZ 40 
exposure; cross-resistance to all tested clinical azoles was observed. The new MIC 41 
value of agricultural and of clinical azoles maintained stable in the absence of the 42 
selective PCZ pressure. PCZ exposure was also associated to morphological colony 43 
changes: macroscopically the colonies became mostly white, losing the typical 44 
pigmentation; microscopic examination revealed the absence of conidiation.  45 
Conclusions: PCZ exposure induced Aspergillus fumigatus morphological changes and 46 
an evident increase of MIC value to PCZ as well as the development of cross-resistance 47 
with posaconazole, itraconazole and voriconazole. 48 
 49 
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Background 51 
The ubiquitous saprophytic mould Aspergillus fumigatus is known to cause a spectrum 52 
of diseases in humans, including allergic syndromes, noninvasive infections, as well as 53 
invasive aspergillosis, a condition associated with significant morbidity and mortality 54 
[1]. A. fumigatus is one of the potentially human pathogenic fungi that have a natural 55 
habitat in the environment, including soil and plants [2]. Some members of the azole 56 
drug class, which includes voriconazole and posaconazole have been shown to be 57 
effective in the treatment of invasive aspergillosis [3]. While azole resistance among 58 
clinical A. fumigatus isolates has for long been considered to be an uncommon finding, 59 
recently multiazole resistance has been reported to be emerging and is increasingly 60 
recognized as a cause of clinical treatment failure [4,5]. In agriculture, thousands of tons 61 
of azoles are sold annually for the purpose of plant protection, either to control fungal 62 
growth that can cause extensive loss of crops or to prevent, or to ease the problem of 63 
postharvest spoilage of plants and fruits [6]. All azoles compounds mode of action - 64 
irrespectively of their chemical structure and variable biological properties - is based on 65 
the interference with the activity of fungal lanosterol 14 alpha-demethylase; such 66 
enzyme is responsible for the transformation of lanosterol in ergosterol, an essential 67 
constituent of the fungal cytoplasmatic membrane which is encoded by Cyp51A gene in 68 
A. fumigatus. The inhibition of ergosterol formation results in cell wall disorganization 69 
and, finally, the impairment of fungal growth. The mode of action of azoles is, 70 
therefore, fungistatic rather than fungicidal. It is well known that a strong and persistent 71 
antimicrobial pressure can lead to the selection of resistant clones within a microbial 72 
population, particularly if the drug effect is static rather than microbicidal [7]. While 73 
fungal diseases are problematic for both human health and agriculture (vegetable and 74 
animal production), the azole class of drugs is the core therapy both for human and 75 
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agricultural fungal diseases. A major concern with this fact is that it may represent an 76 
early step in the emergence of A. fumigatus resistant isolates, driven by the extensive 77 
use of azole fungicides in agriculture, with the same mode of action as azoles used in 78 
humans [7,8,9,10]. Evidence about an environmental route of resistance is gaining 79 
expression [9,10]; findings suggest that it may be responsible for cross-resistance 80 
expressed by clinical and environmental isolates of A. fumigatus across several 81 
countries [11]. The aim of our study was to investigate whether PCZ, a fungicide 82 
extensively use in agriculture, could be associated with the emergence of cross-83 
resistance with clinical azoles amoung A. fumigatus.   84 
 85 
Methods 86 
Organisms  87 
Two clinical isolates of A. fumigatus, LMF05 and LMF11, and one environment A. 88 
fumigatus isolate (LMN60, recovered nearby the hospital), were used in this study. The 89 
isolates were identified as belonging to A. fumigatus species by macroscopic and 90 
microscopic morphology, the ability to grow at 48ºC and by using MALDI-TOF MS to 91 
accurately discriminate A. fumigatus from a new sibling species A. lentulus, which 92 
cannot be distinguished by morphological characteristics or growth peculiarities [12].  93 
Long-term preservation of conidial suspensions of the isolates was made in a GYEP 94 
medium (2% glucose, 0.3% yeast extract, 1% peptone) broth supplemented with 10% 95 
glycerol and stored at -80◦C. Working cultures were subsequently maintained during 2 96 
weeks on Sabouraud dextrose agar slants and plates at 4◦C.  97 
 98 
Antifungal agents and susceptibility profile 99 
 5
Prochloraz (PCZ) was used as a representative of agriculture azoles; Fluconazole (FLC), 100 
Voriconazole (VCZ) Posaconazole (POS) and Itraconazole (ITZ) as selected clinical 101 
azoles. Prochloraz was ressuspended in 80% acetone solution at a final concentration of 102 
5 mg/L. Clinical azoles were dissolved in dimethysulphoxide (DMSO) to obtain stock 103 
solutions of 10 mg/L. All drugs were stored at -20ºC. Broth microdilution susceptibility 104 
assay was performed according to the Clinical and Laboratory Standards Institute M38-105 
A2 protocol in order to evaluate the initial minimal inhibitory concentrations (MIC) of 106 
PCZ and of all the clinical azoles [13]. Drug concentration ranged from 0.125 to 64 107 
mg/L of FLC and PCZ; and 0.0313 to 16 mg/L of POS, VCZ and ITZ. FLC was used as 108 
control, since A. fumigatus shows a non-susceptible phenotype and MIC is most often 109 
above 64 mg/L for this species. MIC of azoles was defined as the lowest concentration 110 
of the drug that produced no visible growth following 48 hours of incubation. MIC 111 
determination was repeated at least twice.  112 
 113 
In vitro induction experiments 114 
Induction experiments were performed with the agricultural azole PCZ. A. fumigatus 115 
isolates were grown on Saboraud dextrose agar at 37ºC for 72h; conidia were harvested 116 
by flooding the surface of the slants with phosphate-buffered saline (PBS) containing 117 
0.025% (vol/vol) tween 80 while gently rocking. The conidial suspensions were then 118 
adjusted using specific spectrometric readings at 550 nm to a final concentration of 119 
5x104 conidia per militer [14]; one militer of each distinct isolate suspension was 120 
transferred to 9 ml of GYEP broth supplemented with sub-inhibitory concentrations of 121 
PCZ and incubated overnight at 37ºC with agitation (180rpm). Daily, after vigorous 122 
vortexing for 60 seconds, one militer from each culture was transferred to fresh GYEP 123 
medium supplemented with PCZ at the concentration of 0.25 mg/L; in parallel, 1 ml of  124 
 6
the culture was added with 10% glycerol and frozen at -80ºC. This procedure was 125 
repeated along thirty consecutive days.  126 
 127 
Susceptibility testing/ Stability of in vitro developed resistance phenotype  128 
MICs of PCZ were determined every five days along the thirty days of induction assay. 129 
No official breakpoints are yet defined for PCZ; therefore, whenever a marked MIC 130 
increase was observed (four fold the initial PCZ MIC), the MIC values of clinical 131 
antifungals were determined.  132 
In order to assess the stability of the developed MIC increment to PCZ and of the 133 
developed cross-resistance to clinical azoles, the induced strains were afterwards sub-134 
cultured for an additional thirty days in the absence of the drug and MIC values re-135 
determined, as previously described.  136 
 137 
Culture macro and micro morphology 138 
Every two days along the induction process, from the successive cultures, a loopful was 139 
inoculated in Saboraud Agar slants to check for viability and purity of culture; the 140 
macro and microscopical growth characteristics were registered; colony morphology 141 
and pigmentation were recorded photographically using a Reflex Nikon D3200 Camera 142 
and images were processed by Adobe Photo Deluxe Image Processing Program (San 143 
Jose, CA, USA). 144 
 145 
Results 146 
In vitro induction assay 147 
The 3 isolates developed a progressive increment of PCZ MIC value comparatively to 148 
the initially determined value. In addition, a concomitant increase of the MIC of VCZ, 149 
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POS and ITZ, was observed (Table 1). From day 0 of evaluation until day 30 during the 150 
induction assay, MIC of PCZ increased 256 times. Concerning the clinical azoles, cross-151 
resistance was developed for all days; all isolates changed from a susceptible to a 152 
resistant phenotype, according to Meletiadis and colleagues [15]. 153 
 154 
Macroscopical and microscopical growth changes during the induction assay 155 
Macroscopic and microscopic morphological alterations were observed following 156 
exposure of A. fumigatus to PCZ.  During the induction assay, initially it was notice a 157 
macroscopic modification of the pigmentation of A.fumigatus colonies, changing from 158 
the initial green colour to white (figure1). With the progressive increase of MIC values 159 
of PCZ, colonies of A. fumigatus expressed dramatic changes, resulting in totally white, 160 
scanty and sparse colonies. Microscopic examination in detail of such white colonies 161 
showed almost complete absence of conidiation, the white mycelia corresponding solely 162 
to hyphae. 163 
 164 
Stability of the in vitro developed resistant phenotype  165 
The in vitro developed high MIC values of PCZ maintained stable following removal of 166 
the selective pressure of the drug. For VRC, the MIC value decreased only after 30 days 167 
of incubation without the selective pressure, changing the susceptibility phenotype from 168 
resistant to intermediate. For POS, the developed MIC value also decreased but not 169 
enough to change the phenotype of resistance. Regarding ITZ, it was observed the 170 
complete reversibility of the resistant phenotype in the absence of PCZ, ie, the MIC 171 
reverted to the initial value and that value is categorize as susceptible. Following 172 
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removal of the selective pressure of PCZ, conidiation reappeared together with the 173 
green typical color of mature colonies, in all isolates. 174 
 175 
Discussion 176 
While very few studies have characterized azole resistance in A. fumigatus, some 177 
addressed the possible cross-resistance between environmental and medical azoles 178 
[8,9,10,11]. Our study demonstrated the time frame between the introduction of a 179 
widely used agricultural fungicide and the emergence of cross-resistance to medical 180 
triazoles. The exposure of other clinical relevant moulds to agricultural azoles might 181 
therefore be associated with the emergence of cross-resistance to clinical antifungals. 182 
Besides the emergence of cross-resistance, we found that PCZ exposure caused marked 183 
morphological colony changes, both at macroscopical level (the colonies turned white 184 
losing the characteristical pigmentation) and microscopic: detailed examination revealed 185 
the absence of conidia. Changes in the pigmentation of A. fumigatus colonies and the 186 
absence of conidia as consequence of azoles’ effect have already been reported [16]. 187 
Notably, such morphological changes may be responsible for laboratorial diagnostic 188 
misidentification of the fungal genus/species, following its initial isolation, with the 189 
inherent consequences. 190 
The possibility of development of A. fumigatus clones resistant to medical triazoles 191 
stresses the need to find safer alternative compounds to agriculture azoles.  Since PCZ 192 
was responsible for the emergence of stable resistance to itself and to very important 193 
medical triazoles in A. fumigatus, a resistance mechanism might have been developed. 194 
Previous reports describe cyp51A mutation, efflux pump overexpression and/or target 195 
upregulation the main mechanisms responsible for such resistance [17,18,19]. Certainly, 196 
our next study is to unveil the underlying molecular mechanism. Meanwhile, our study 197 
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strongly suggests that the abuse of environmental azoles might cause serious veterinary 198 
and human health problems in particular to immunocompromised patients, a high risk 199 
population for invasive aspergilosis. Azole-resistance and cross-resistance has the 200 
potential to further compromise the efficacy of clinical azoles in the future [4,19,20,21]. 201 
Very recently, several compounds were screened in order to find new antifungal 202 
alternatives preventing the possible loss of efficacy of clinical azoles [22].  203 
 204 
Conclusions 205 
In order to assess the real dimension of Aspergillus resistance, a susceptibility test 206 
should be performed in all isolates from patients with Aspergillus infection. Moreover, 207 
initial combination therapy may be considered, in geographical areas with high 208 
prevalence of environmental azole resistant isolates, for patients with severe infection. 209 
Ultimately, surveillance studies in both clinical settings and in the environment should 210 
be conducted in order to provide updated local data regarding susceptibility profiles. 211 
 212 
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Figure 1 – Photographs of Sabouraud dextrose agar plates showing macroscopic 297 
morphological changes of colonies of A. fumigatus following exposure to subinhibitory 298 
concentration of PCZ.  299 
A. Initial morphological aspect (control). 300 
B. After fifteen days. 301 
C. After thirty days.  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322 
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Table 1 Susceptibility pattern of tested A.fumigatus isolates to Prochloraz and clinical 323 
azoles. 324 
 325  326 A. fumigatus isolate Time of exposure (days) MIC (mg/L) PCZ VRC POS ITZ FLC 
LMF05 
0 0.125 0.125 0.25 2 >64 
10 0.25 0.25 0.5 2 >64 
20 8 2 1 4 >64 
30 32 8 2 8 >64 
 ∅30 32 2 2 2 >64 
LMF11 
0 0.125 0.25 0.125 0.5 >64 
10 0.125 2 0.25 1 >64 
20 8 8 1 2 >64 
30 32 >16 4 4 >64 
 ∅30 32 2 1 0.5 >64 
LMN60 
0 0.25 0.25 0.125 0.25 >64 
10 4 8 0.25 1 >64 
20 8 8 0.5 2 >64 
30 64 >16 4 4 >64 
 ∅30 64 2 1 0.25 >64 
PCZ= Prochloraz; VCZ= Voriconazole; POS= Posaconazole; ITZ= Itraconazole; 
FLU= Fluconazole; ∅= MIC after 30 days of culture in the absence of PCZ. 
Figure 1
Figure 2
Figure 3
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can be accepted for the main manuscript document by the online 
submission system. Additional files of any type, such as movies, 
animations, or original data files, can also be submitted as part of the 
manuscript. 
During submission you will be asked to provide a cover letter. Use this to 
explain why your manuscript should be published in the journal, to 
elaborate on any issues relating to our editorial policies in the 'About BMC 
Microbiology' page, and to declare any potential competing interests. You 
will be also asked to provide the contact details (including email 
addresses) of potential peer reviewers for your manuscript. These should 
be experts in their field, who will be able to provide an objective 
assessment of the manuscript. Any suggested peer reviewers should not 
have published with any of the authors of the manuscript within the past 
five years, should not be current collaborators, and should not be 
members of the same research institution. Suggested reviewers will be 
considered alongside potential reviewers recommended by the Editorial 
team, Editorial Advisors, Section Editors and Associate Editors. 
Assistance with the process of manuscript preparation and submission is 
available from BioMed Central customer support team. 
We also provide a collection of links to useful tools and resources for 
scientific authors on our Useful Tools page. 
File formats 
The following word processor file formats are acceptable for the main 
manuscript document: 
  Microsoft word (DOC, DOCX) 
  Rich text format (RTF) 
  Portable document format (PDF) 
  TeX/LaTeX (use BioMed Central's TeX template) 
  DeVice Independent format (DVI) 
TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX 
stylefile if you use TeX format. During the TeX submission process, please 
submit your TeX file as the main manuscript file and your bib/bbl file as a 
dependent file. Please also convert your TeX file into a PDF and submit 
this PDF as an additional file with the name 'Reference PDF'. This PDF will 
be used by internal staff as a reference point to check the layout of the 
article as the author intended. Please also note that all figures must be 
coded at the end of the TeX file and not inline. 
If you have used another template for your manuscript, or if you do not 
wish to use BibTeX, then please submit your manuscript as a DVI file. We 
do not recommend converting to RTF. 
For all TeX submissions, all relevant editable source must be submitted 
during the submission process. Failing to submit these source files will 
cause unnecessary delays in the publication procedures. 
Publishing Datasets 
Through a special arrangement with LabArchives, LLC, authors submitting 
manuscripts to BMC Microbiology can obtain a complimentary subscription 
to LabArchives with an allotment of 100MB of storage. LabArchives is an 
Electronic Laboratory Notebook which will enable scientists to share and 
publish data files in situ; you can then link your paper to these data. Data 
files linked to published articles are assigned digital object identifiers 
(DOIs) and will remain available in perpetuity. Use of LabArchives or 
similar data publishing services does not replace preexisting data 
deposition requirements, such as for nucleic acid sequences, protein 
sequences and atomic coordinates. 
Instructions on assigning DOIs to datasets, so they can be permanently 
linked to publications, can be found on the LabArchives website. Use of 
LabArchives’ software has no influence on the editorial decision to accept 
or reject a manuscript. 
Authors linking datasets to their publications should include an Availability 
of supporting data section in their manuscript and cite the dataset in their 
reference list. 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Research 
articles 
Manuscripts for Research articles submitted to BMC Microbiology should 
be divided into the following sections (in this order): 
  Title page 
  Abstract 
  Keywords 
  Background 
  Results and discussion 
  Conclusions 
  Methods (can also be placed after Background) 
  Availability of supporting data 
  List of abbreviations used (if any) 
  Competing interests 
  Authors' contributions 
  Authors' information 
  Acknowledgements 
  Endnotes 
  References 
  Illustrations and figures (if any) 
  Tables and captions 
  Preparing additional files 
The Accession Numbers of any nucleic acid sequences, protein 
sequences or atomic coordinates cited in the manuscript should be 
provided, in square brackets and include the corresponding database 
name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, 
GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. 
The databases for which we can provide direct links are: EMBL Nucleotide 
Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at 
the NCBI (GenBank), Protein Data Bank (PDB), Protein Information 
Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot). 
You can download a template (Mac and Windows compatible; Microsoft 
Word 98/2000) for your article. 
For reporting standards please see the information in the About section. 
Title page 
The title page should: 
  provide the title of the article 
  list the full names, institutional addresses and email addresses for 
all authors 
  indicate the corresponding author 
Please note: 
  abbreviations within the title should be avoided 
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be 
structured into separate sections: Background, the context and purpose 
of the study; Results, the main findings; Conclusions, brief summary 
and potential implications. Please minimize the use of abbreviations and 
do not cite references in the abstract. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background 
The Background section should be written in a way that is accessible to 
researchers without specialist knowledge in that area and must clearly 
state - and, if helpful, illustrate - the background to the research and its 
aims. The section should end with a brief statement of what is being 
reported in the article. 
Results and discussion 
The Results and discussion may be combined into a single section or 
presented separately. The Results and discussion sections may also be 
broken into subsections with short, informative headings. 
Conclusions 
This should state clearly the main conclusions of the research and give a 
clear explanation of their importance and relevance. Summary 
illustrations may be included. 
Methods 
The methods section should include the design of the study, the type of 
materials involved, a clear description of all comparisons, and the type of 
analysis used, to enable replication. 
For studies involving human participants a statement detailing ethical 
approval and consent should be included in the methods section. For 
further details of the journal's editorial policies and ethical guidelines see 
'About this journal'. 
For further details of the journal's data-release policy, see the policy 
section in 'About this journal'. 
Availability of supporting data 
BMC Microbiology encourages authors to deposit the data set(s) 
supporting the results reported in submitted manuscripts in a publicly-
accessible data repository, when it is not possible to publish them as 
additional files. This section should only be included when supporting data 
are available and must include the name of the repository and the 
permanent identifier or accession number and persistent hyperlink(s) for 
the data set(s). The following format is required: 
"The data set(s) supporting the results of this article is(are) available in 
the [repository name] repository, [unique persistent identifier and 
hyperlink to dataset(s) in http:// format]." 
Where all supporting data are included in the article or additional files the 
following format is required: 
"The data set(s) supporting the results of this article is(are) included 
within the article (and its additional file(s))" 
We also recommend that the data set(s) be cited, where appropriate in 
the manuscript, and included in the reference list. 
A list of available scientific research data repositories can be found here. A 
list of all BioMed Central journals that require or encourage this section to 
be included in research articles can be found here. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at 
first use, and a list of abbreviations can be provided, which should 
precede the competing interests and authors' contributions. 
Competing interests 
A competing interest exists when your interpretation of data or 
presentation of information may be influenced by your personal or 
financial relationship with other people or organizations. Authors must 
disclose any financial competing interests; they should also reveal any 
non-financial competing interests that may cause them embarrassment 
were they to become public after the publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All 
competing interests that are declared will be listed at the end of published 
articles. Where an author gives no competing interests, the listing will 
read 'The author(s) declare that they have no competing interests'. 
When completing your declaration, please consider the following 
questions: 
Financial competing interests 
  In the past five years have you received reimbursements, fees, 
funding, or salary from an organization that may in any way gain or 
lose financially from the publication of this manuscript, either now 
or in the future? Is such an organization financing this manuscript 
(including the article-processing charge)? If so, please specify. 
  Do you hold any stocks or shares in an organization that may in 
any way gain or lose financially from the publication of this 
manuscript, either now or in the future? If so, please specify. 
  Do you hold or are you currently applying for any patents relating 
to the content of the manuscript? Have you received 
reimbursements, fees, funding, or salary from an organization that 
holds or has applied for patents relating to the content of the 
manuscript? If so, please specify. 
  Do you have any other financial competing interests? If so, please 
specify. 
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, 
religious, ideological, academic, intellectual, commercial or any other) to 
declare in relation to this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a 
competing interest please discuss it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the 
individual contributions of authors to the manuscript should be specified in 
this section. 
According to ICMJE guidelines, An 'author' is generally considered to be 
someone who has made substantive intellectual contributions to a 
published study. To qualify as an author one should 1) have made 
substantial contributions to conception and design, or acquisition of data, 
or analysis and interpretation of data; 2) have been involved in drafting 
the manuscript or revising it critically for important intellectual content; 3) 
have given final approval of the version to be published; and 4) agree to 
be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. Each author should have 
participated sufficiently in the work to take public responsibility for 
appropriate portions of the content. Acquisition of funding, collection of 
data, or general supervision of the research group, alone, does not justify 
authorship. 
We suggest the following kind of format (please use initials to refer to 
each author's contribution): AB carried out the molecular genetic studies, 
participated in the sequence alignment and drafted the manuscript. JY 
carried out the immunoassays. MT participated in the sequence alignment. 
ES participated in the design of the study and performed the statistical 
analysis. FG conceived of the study, and participated in its design and 
coordination and helped to draft the manuscript. All authors read and 
approved the final manuscript. 
All contributors who do not meet the criteria for authorship should be 
listed in an acknowledgements section. Examples of those who might be 
acknowledged include a person who provided purely technical help, 
writing assistance, or a department chair who provided only general 
support. 
Authors' information 
You may choose to use this section to include any relevant information 
about the author(s) that may aid the reader's interpretation of the article, 
and understand the standpoint of the author(s). This may include details 
about the authors' qualifications, current positions they hold at institutions 
or societies, or any other relevant background information. Please refer to 
authors using their initials. Note this section should not be used to 
describe any competing interests. 
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content, but who does not meet the criteria for authorship. Please also 
include the source(s) of funding for each author, and for the manuscript 
preparation. Authors must describe the role of the funding body, if any, in 
design, in the collection, analysis, and interpretation of data; in the 
writing of the manuscript; and in the decision to submit the manuscript 
for publication. Please also acknowledge anyone who contributed 
materials essential for the study. If a language editor has made significant 
revision of the manuscript, we recommend that you acknowledge the 
editor by name, where possible. 
Authors should obtain permission to acknowledge from all those 
mentioned in the Acknowledgements section. 
Endnotes 
Endnotes should be designated within the text using a superscript 
lowercase letter and all notes (along with their corresponding letter) 
should be included in the Endnotes section. Please format this section in a 
paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square 
brackets, in the order in which they are cited in the text, followed by any 
in tables or legends. Each reference must have an individual reference 
number. Please avoid excessive referencing. If automatic numbering 
systems are used, the reference numbers must be finalized and the 
bibliography must be fully formatted before submission. 
Only articles, datasets and abstracts that have been published or are in 
press, or are available through public e-print/preprint servers, may be 
cited; unpublished abstracts, unpublished data and personal 
communications should not be included in the reference list, but may be 
included in the text and referred to as "unpublished observations" or 
"personal communications" giving the names of the involved researchers. 
Obtaining permission to quote personal communications and unpublished 
data from the cited colleagues is the responsibility of the author. 
Footnotes are not allowed, but endnotes are permitted. Journal 
abbreviations follow Index Medicus/MEDLINE. Citations in the reference 
list should include all named authors, up to the first 30 before adding 'et 
al.'.. 
Any in press articles cited within the references and necessary for the 
reviewers' assessment of the manuscript should be made available if 
requested by the editorial office. 
Style files are available for use with popular bibliographic management 
software: 
  BibTeX 
  EndNote style file 
  Reference Manager 
  Zotero 
Examples of the BMC Microbiology reference style are shown below. 
Please ensure that the reference style is followed precisely; if the 
references are not in the correct style they may have to be retyped and 
carefully proofread. 
All web links and URLs, including links to the authors' own websites, 
should be given a reference number and included in the reference list 
rather than within the text of the manuscript. They should be provided in 
full, including both the title of the site and the URL, in the following 
format: The Mouse Tumor Biology Database 
[http://tumor.informatics.jax.org/mtbwi/index.do]. If an author or group 
of authors can clearly be associated with a web link, such as for weblogs, 
then they should be included in the reference. 
Examples of the BMC Microbiology reference style 
 
Article within a journal Koonin EV, Altschul SF, Bork P: BRCA1 protein 
products: functional motifs. Nat Genet 1996, 13:266-267. 
Article within a journal supplement Orengo CA, Bray JE, Hubbard T, 
LoConte L, Sillitoe I: Analysis and assessment of ab initio three-
dimensional prediction, secondary structure, and contacts 
prediction. Proteins 1999, 43(Suppl 3):149-170. 
In press article Kharitonov SA, Barnes PJ: Clinical aspects of exhaled 
nitric oxide. Eur Respir J, in press. 
Published abstract Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor 
P, Maini RN: Mesenchymal cells, stromal derived factor-1 and 
rheumatoid arthritis [abstract]. Arthritis Rheum 1999, 42:s250. 
Article within conference proceedings Jones X: Zeolites and synthetic 
mechanisms. In Proceedings of the First National Conference on Porous 
Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y. Stoneham: 
Butterworth-Heinemann; 1996:16-27. 
Book chapter, or article within a book Schnepf E: From prey via 
endosymbiont to plastids: comparative studies in dinoflagellates. 
In Origins of Plastids. Volume 2. 2nd edition. Edited by Lewin RA. New 
York: Chapman and Hall; 1993:53-76. 
Whole issue of journal Ponder B, Johnston S, Chodosh L (Eds): 
Innovative oncology. In Breast Cancer Res 1998, 10:1-72. 
Whole conference proceedings Smith Y (Ed): Proceedings of the First 
National Conference on Porous Sieves: 27-30 June 1996; Baltimore. 
Stoneham: Butterworth-Heinemann; 1996. 
Complete book Margulis L: Origin of Eukaryotic Cells. New Haven: Yale 
University Press; 1970. 
Monograph or book in a series Hunninghake GW, Gadek JE: The alveolar 
macrophage. In Cultured Human Cells and Tissues. Edited by Harris TJR. 
New York: Academic Press; 1995:54-56. [Stoner G (Series Editor): 
Methods and Perspectives in Cell Biology, vol 1.] 
Book with institutional author Advisory Committee on Genetic 
Modification: Annual Report. London; 1999. 
PhD thesis Kohavi R: Wrappers for performance enhancement and 
oblivious decision graphs. PhD thesis. Stanford University, Computer 
Science Department; 1995. 
Link / URL The Mouse Tumor Biology Database 
[http://tumor.informatics.jax.org/mtbwi/index.do] 
Link / URL with author(s) Neylon C: Open Research Computation: an 
ordinary journal with extraordinary aims. 
[http://blogs.openaccesscentral.com/blogs/bmcblog/entry/open_research
_computation_an_ordinary] 
Dataset with persistent identifier Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; 
Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; Liu, C-M; Jing, 
H-C (2011): Genome data from sweet and grain sorghum (Sorghum 
bicolor). GigaScience. http://dx.doi.org/10.5524/100012. 
Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the 
text file. Each figure should include a single illustration and should fit on a 
single page in portrait format. If a figure consists of separate parts, it is 
important that a single composite illustration file be submitted which 
contains all parts of the figure. There is no charge for the use of color 
figures. 
Please read our figure preparation guidelines for detailed instructions on 
maximising the quality of your figures. 
Formats 
The following file formats can be accepted: 
  PDF (preferred format for diagrams) 
  DOCX/DOC (single page only) 
  PPTX/PPT (single slide only) 
  EPS 
  PNG (preferred format for photos or images) 
  TIFF 
  JPEG 
  BMP 
Figure legends 
The legends should be included in the main manuscript text file at the end 
of the document, rather than being a part of the figure file. For each 
figure, the following information should be provided: Figure number (in 
sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of 
figure (maximum 15 words); detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain 
permission from the copyright holder to reproduce figures or 
tables that have previously been published elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of 
publication, will be used to create a cover page for the PDF version of your 
article. The cover page will also display the journal logo, article title and 
citation details. The image may either be a figure from your manuscript or 
another relevant image. You must have permission from the copyright to 
reproduce the image. Images that do not meet our requirements will not 
be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a 
raster image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for 
photographs and screen dumps), JPEG, BMP, DOC, PPT, CDX, TGF 
(ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic 
numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a title (above 
the table) that summarizes the whole table; it should be no longer than 
15 words. Detailed legends may then follow, but they should be concise. 
Tables should always be cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted 
into the end of the document text file, in A4 portrait or landscape format. 
These will be typeset and displayed in the final published form of the 
article. Such tables should be formatted using the 'Table object' in a word 
processing program to ensure that columns of data are kept aligned when 
the file is sent electronically for review; this will not always be the case if 
columns are generated by simply using tabs to separate text. Columns 
and rows of data should be made visibly distinct by ensuring that the 
borders of each cell display as black lines. Commas should not be used to 
indicate numerical values. Color and shading may not be used; parts of 
the table can be highlighted using symbols or bold text, the meaning of 
which should be explained in a table legend. Tables should not be 
embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a portrait page can be uploaded 
separately as additional files. Additional files will not be displayed in the 
final, laid-out PDF of the article, but a link will be provided to the files as 
supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel 
spreadsheet (.xls ) or comma separated values (.csv). As with all files, 
please use the standard file extensions. 
Preparing additional files 
Although BMC Microbiology does not restrict the length and quantity of 
data included in an article, we encourage authors to provide datasets, 
tables, movies, or other information as additional files. 
Please note: All Additional files will be published along with the article. 
Do not include files such as patient consent forms, certificates of language 
editing, or revised versions of the main manuscript document with tracked 
changes. Such files should be sent by email to 
editorial@biomedcentral.com, quoting the Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and 
should be included as additional files. Since many weblinks and URLs 
rapidly become broken, BMC Microbiology requires that supporting data 
are included as additional files, or deposited in a recognized repository. 
Please do not link to data on a personal/departmental website. The 
maximum file size for additional files is 20 MB each, and files will be virus-
scanned on submission. 
Additional files can be in any format, and will be downloadable from the 
final published article as supplied by the author. We recommend CSV 
rather than PDF for tabular data. 
Certain supported files formats are recognized and can be displayed to the 
user in the browser. These include most movie formats (for users with the 
Quicktime plugin), mini-websites prepared according to our guidelines, 
chemical structure files (MOL, PDB), geographic data files (KML). 
If additional material is provided, please list the following information in a 
separate section of the manuscript text: 
  File name (e.g. Additional file 1) 
  File format including the correct file extension for example .pdf, 
.xls, .txt, .pptx (including name and a URL of an appropriate viewer 
if format is unusual) 
  Title of data 
  Description of data 
Additional files should be named "Additional file 1" and so on and should 
be referenced explicitly by file name within the body of the article, e.g. 
'An additional movie file shows this in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and 
should be viewable using free or widely available tools. The following are 
examples of suitable formats. 
  Additional documentation 
  PDF (Adode Acrobat) 
  Animations 
  SWF (Shockwave Flash) 
  Movies 
  MP4 (MPEG 4) 
  MOV (Quicktime) 
  Tabular data 
  XLS, XLSX (Excel Spreadsheet) 
  CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such 
a way that they will be browsable from within the full text HTML version of 
the article. In order to do this, please follow these instructions: 
1. Create a folder containing a starting file called index.html (or 
index.htm) in the root. 
2. Put all files necessary for viewing the mini-website within the folder, or 
sub-folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than 
"/images/picture.jpg" or 
"http://yourdomain.net/images/picture.jpg" or "C:\Documents and 
Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 
characters. 
4. Access the index.html file and browse around the mini-website, to 
ensure that the most commonly used browsers (Internet Explorer 
and Firefox) are able to view all parts of the mini-website without 
problems, it is ideal to check this on a different machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, 
ensure that index.html is in the root of the ZIP, and that the file 
has .zip extension, then submit as an additional file with your 
article. 
Style and language 
General 
Currently, BMC Microbiology can only accept manuscripts written in 
English. Spelling should be US English or British English, but not a 
mixture. 
There is no explicit limit on the length of articles submitted, but authors 
are encouraged to be concise. 
BMC Microbiology will not edit submitted manuscripts for style or 
language; reviewers may advise rejection of a manuscript if it is 
compromised by grammatical errors. Authors are advised to write clearly 
and simply, and to have their article checked by colleagues before 
submission. In-house copyediting will be minimal. Non-native speakers of 
English may choose to make use of a copyediting service. 
Language editing 
For authors who wish to have the language in their manuscript edited by a 
native-English speaker with scientific expertise, BioMed Central 
recommends Edanz. BioMed Central has arranged a 10% discount to the 
fee charged to BioMed Central authors by Edanz. Use of an editing service 
is neither a requirement nor a guarantee of acceptance for publication. 
Please contact Edanz directly to make arrangements for editing, and for 
pricing and payment details. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For 
guidance, please visit our page on Writing titles and abstracts for scientific 
articles. 
Tim Albert has produced for BioMed Central a list of tips for writing a 
scientific manuscript. American Scientist also provides a list of resources 
for science writing. For more detailed guidance on preparing a manuscript 
and writing in English, please visit the BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be 
defined when first used and a list of abbreviations can be provided 
following the main manuscript text. 
Typography 
  Please use double line spacing. 
  Type the text unjustified, without hyphenating words at line breaks. 
  Use hard returns only to end headings and paragraphs, not to 
rearrange lines. 
  Capitalize only the first word, and proper nouns, in the title. 
  All lines and pages should be numbered. Authors are asked to 
ensure that line numbering is included in the main text file of their 
manuscript at the time of submission to facilitate peer-review. Once 
a manuscript has been accepted, line numbering should be 
removed from the manuscript before publication. For authors 
submitting their manuscript in Microsoft Word please do not insert 
page breaks in your manuscript to ensure page numbering is 
consistent between your text file and the PDF generated from your 
submission and used in the review process. 
  Use the BMC Microbiology reference format. 
  Footnotes are not allowed, but endnotes are permitted. 
  Please do not format the text in multiple columns. 
  Greek and other special characters may be included. If you are 
unable to reproduce a particular special character, please type out 
the name of the symbol in full. Please ensure that all special 
characters used are embedded in the text, otherwise they 
will be lost during conversion to PDF. 
  Genes, mutations, genotypes, and alleles should be indicated in 
italics, and authors are required to use approved gene symbols, 
names, and formatting. Protein products should be in plain type. 
Units 
SI units should be used throughout (liter and molar are permitted, 
however).	  
